JABSOM) welcomed 77 first-year medical students into its new curricular initiative, the Learning Community program. The anticipated positive impact of this pioneering medical education on health care delivery has resulted in the
HMSA Foundation adding to its initial support of the program, donating $5 million to establish the
HMSA Learning Innovations Endowment to support innovative medical education.
First-year medical students (Class of 2024).
The Learning Innovations Center within the Office of Medical Education at
JABSOM will continue to evolve medical training to meet the changing needs of Hawaiʻi’s health care system. The center will be named the
HMSA Learning Innovations Center in recognition of
Updated: 1:30 PM CST January 25, 2021
MEMPHIS, Tenn. Researchers at the University of Tennessee Health Science Center have played a supporting role in the development of COVID-19 vaccines.
To examine the efficacy of the Pfizer-BioNTech vaccine during development, the company needed a way to test the inhibitory effects of the antibodies generated after vaccination on virus infection. However, to work with SARS-CoV-2 requires a Biosafety Level-3 laboratory, which most companies do not have. To reduce the risk to workers testing the vaccine, Pfizer-BioNTech and other companies developing vaccines against COVID-19 have utilized a surrogate system, one of which was developed in the laboratory of Michael Whitt, PhD, associate dean of the Office of Medical Education in the UTHSC College of Medicine, chair of the Department of Medical Education, and a professor and former chair of the Department of Microbiology, Immunology, and Biochemistry at the University of Tennessee